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I. INTRODUCTION
On August 9th, 2001, President George W. Bush announced his
decision to allow federal government funding for human embryonic stem
cell research. 1 The President's decision limited funding to research on
existing embryonic stem cell lines only, due to the moral and ethical issues
surrounding this type of research. 2 In addition, President Bush approved

• This Note is dedicated to my family. You have always been my source of encouragement
and inspiration, for which I am eternally grateful. Thank you for always being there. This Note
received the Barbara W. Makar Writing Award for the outstanding note for Fall 2001.
1. Remarks by President George W. Bush on Stem Cell Research, at http://www.white
house.gov/news/releases/2001/08/20010809-2.html (Aug. 9, 2001).
2. See id. at 3.
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aggressive funding for research on human adult stem cells, along with
research on stem cells derived from umbilical cord, placenta, and animals. 3
This decision was based upon the belief that such research would lead to
breakthrough scientific discoveries that would result in treatments and
cures for a myriad of diseases and ailments that affect people worldwide. 4
Describing stem cell research as a "new frontier," 5 the President's decision
to allow stem cell research funding is the first step toward turning science
fiction into fact.
Even without federal funding, researchers have undertaken the tasks of
stem cell discovery. 6 While federal funds greatly aid the research process,
private companies have incentives of their own. The possibility of
financial gains from new technologies and inventions borne from research
influences companies to invest in the research and development of such
technologies. These financial rewards are embodied in intellectual
property rights and may be manifested in the area of biotechnology in the
form oflicensing agreements involving patented inventions and processes.
These patent rights are provided by the federal government, through 3 5
U.S.C. §§ 100-57 (Patent Act),7 as a means to promote technological
advancement. 8 However, for public policy purposes, the availability of this
protection is limited.
This Article explores the patentability of the theoretical results of
human embryonic stem cell research. Section II provides background
information regarding embryonic stem cells. Section III provides an
overview of general patent law and the requirements for patentability.
Section IV deals with patent protection of biological organisms, including
the availability of patent protection for human DNA and gene sequences.
Section V concludes with a discussion and application ofthe current patent
laws to possible future inventions and discoveries due to stem cell
research.

3. President Bush stated that the federal government would spend $250 million on this form
ofresearch. Id.
4. Id.
5. Id
6. Private researchers have created more than sixty distinct stem cell lines. Remarks by
President George W. Bush, supra note 1, at 3.
7. 35 U.S.C. §§ 100-157 (2001).
8. See Kevin Cuenot, Perilous Potholes in the Path Toward Patent Law Harmonization, 11
U. FLA. J.L. & PUB. POL'Y 101, 101 (1999).
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II. HUMAN EMBRYONIC STEM CELL RESEARCH
The use of human embryonic stem cells for research purposes has
received national and international attention. 9 In fact, President Bush's
decision to allow federal funding for stem cell research was not the first
time this issue was reviewed by the Office of the President. In November
1998, President Bill Clinton ordered the National Bioethics Advisory
Commission to review and balance all of the ethical and medical
considerations involved with this form of research. 10 But what is a human
embryonic stem cell?
A. Human Embryonic Stem Cells
At the cellular level, the human body is composed of millions of cells. 11
These cells are different, based upon the tissues or organs that they
comprise. 12 However, all of these cells have the same origin, thus, the cells
that make up the brain were at one point identical to the cells that make up
the heart. This origin is the embryonic stem cell. Stem cells are
undifferentiated cells that are able to undergo indefinite cell division and
that have the ability to become any type of specialized cells. 13 In humans,
these cells are created following fertilization of an egg cell by a sperm cell.
During normal human development, gametes 14 fuse at fertilization,
creating a single cell zygote. 15 This cell has the potential, under the proper

9. See National Bioethics Advisory Commission, Ethical Issues in Human Stem Cell
Research, Executive Summary at 2, at http://bioethics.georgetown.edu/nbac/pubs.html (Sept. 1999).
10. Id. at I.
11. GERALD J. TORTORA & SANDRA REYNOLDS GRABOWSKI, PRINCIPLES OF ANATOMY AND
PHYSIOLOGY 7 (8th ed. 1996). The human body is composed of eleven different "systems" each
made up of organs which consist of millions of cells. Id.
12. See id. at 94-119 (discussing the major classifications of body tissues, including cell
differences between them). See also DOUGLAS E. KELL y ET AL., BAILEY'S TExTBOOK OF
MICROSCOPIC ANATOMY 17 (Toni M. Tracy ed., 18th ed. 1984) (stating that the various shapes,
sizes, and composition of cells is due to their functions in different tissues and organs of the body).
13. See National Institutes of Health, Stem Cells: A Primer I, at http://www.nih.gov/news/
stemcell/primer.htm (May 2000). Stem cells undergo differentiation, the changes that cause a cell
to develop from an unspecialized cell to a specialized, or specific cell type. See also TORTORA &
GRABOWSKI, supra note 11, at 83.
14. Gametes or sperm and egg cells are the human reproductive cells. See TORTORA &
GRABOWSKI, supra note 11, at 83.
15. Id. A zygote is the single cell produced from gamete fusion (fertilization). This cell
contains a DNA set from each parent, and has the potential to develop into another human being.
Id.
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conditions, to divide and grow, eventually forming a viable human being. 16
Following fertilization, the zygote undergoes several rounds of cell
division, 17 creating identical cells. 18 These duplicate cells all have the
possibility to differentiate into any of the various cell types in the human
body. These cells eventually begin to specialize to form a blastocyst, an
early structure in the embryonic process. 19 This structure is made up of two
distinct cell types, the outer cells which will ultimately form the tissues
and structures required to support fetal development in the uterus, and the
inner cell mass, a group of cells which will ultimately differentiate to form
all of the various cells of the human body. 20 The cells in this inner mass are
embryonic stem cells. 21
The differentiation of these stem cells occurs in part from the activation
of certain genes within the cells' nuclei. 22 These genes are comprised of
deoxyribonucleic acid (DNA), and once activated, will produce specific
proteins and other biochemical materials that will determine the future
identity of each cell. 23 Thus, prior to this gene expression, stem cells have
the potential to become any type of cell in the human body. 24

B. The Potential ofStem Cell Research
Stem cell research may lead to discoveries that can be used to treat a
multitude of human diseases. 25 These discoveries may provide cures for
diseases which have yet to be uncovered by current medical research. 26
Stem cell research may also provide scientists with a better understanding

16. See National Institutes of Health, supra note 13.
17. The zygote undergoes cell division, during which DNA, the genetic material enclosed in
the dividing cell's nucleus, is duplicated. TORTORA & GRABOWSKI, supra note 11, at 80-83. The
cell divides, forming two identical cells. Id. at 80. During this process, the number of identical cells
i~c~e~es exp~nentially. Id. at 80-83. This process continues until a signal is given to the cell
dms1on machmery to cease dividing. Id.
18. See National Institutes of Health, supra note 13.
19. Id.
20. Id. at 1-2.
21. Id. at 2.
22. SCOTT F. GILBERT, DEVELOPMENTAL BIOLOGY 97 (6th ed. 2000).
23. Id. at 5~. Cell differentiation involves biochemical changes. Id.
2 4 . See National Cancer Institute, Institutes and Centers Answers to the Question: "What
Would You Hope to Achieve From Human Pluripotent Stem Cell Research?," at http://www.nih.
gov/news/stemcel_l/achieve.htm (Apr. 26, 2000).
25 - See White House Press Release, Fact Sheet, Embryonic Stem Cell Research 2, at http://
www.whitehouse.gov/news/releases/2001/08/200 I 0809-1.html (Aug. 9, 2001 ).
26. See id.
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ofhuman biological functions. 27 Furthermore, new means ofevaluating the
safety and effectiveness of existing and newly developed drugs may result
from stem cell research. 28
Researchers believe that stem cells will play an important role in cancer
research, treatment, and cures. 29 Diseases of the nervous system, such as
Parkinson's and Alzheimer's disease may eventually be treated and even
cured through stem cell developed technology. 30 Even more incredible,
damage to the nervous system due to stroke and spinal cord injuries may
be reversed; 31 thus, stem cell research may one day lead to a cure for
paralysis by regenerating severed spinal cord tissue. In addition,
researchers believe that diseases such as acquired immunodeficiency
syndrome (AIDS) may be treated effectively in the future as a result of
stem cell research. 32
In addition to advances in the treatment of diseases, stem cell research
could lead to the capability of regenerating damaged organs or the creation
of new organs for transplantation purposes. 33 This could be possible once
researchers uncover the specific processes of cell specialization and gene

27. See id.
28. Id.
29. National Cancer Institute, supra note 24, at 1. Researchers at the National Cancer
Institute (NCI) believe that stem cells may be the key to unlocking the mystery of cancer cell
proliferation and resistance to current methods of treatment. The NCI also feels that stem cells may
one day be utilized to replenish tissues and organs damaged by current chemotherapy treatments.
Id. Currently, adult bone marrow and blood stem cells are used for such purposes. These cells are
further differentiated than embryonic stem cells, however, and lack the potential of such cells. Id.
30. See id. at 7. Both the National Institute of Neurological Disorders and Stroke and the
National Institute on Aging support the "enormous potential" stem cell research may have on
developing cell and tissue replacement therapies on these degenerative neurological diseases. Id.
These diseases occur as a result of lost nerve cells, which cannot be replaced by mature nerve cells
due to their inability to undergo cell division. Id. However, experiments involving stem cell
replacement therapies on animals have shown promising results that these nerve cells may one day
be replaced using stem cells. Id. at 8. See also Remarks by President George W. Bush, supra note
1; White House Press Release, supra note 25.
31. See National Cancer Institute, supra note 24, at 3.
32. The National Institute of Allergy and Infectious Diseases asserts that stem cell research
may yield results that help restore immune functions damaged or destroyed by HIV infection. Id.
at 5.
33. See Remarks by President George W. Bush, supra note 1. This could alleviate the current
discrepancy between those individuals requiring organ transplants and the number of organs
available for transplantation. See also National Institutes of Health, supra note 13, at 3.
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activation. 34 Using stem cells, researchers may be able to gain valuable
insight into the operations of the human genome and into human biology,
ultimately using this knowledge to create in vitro tissues and organs for
transplantation. 35
Not only may stem cells be valuable for direct use in the treatment and
cure of diseases, stem cell research may provide new means of developing
and testing the effectiveness and safety of medicines. 36 Stem cell lines
could allow drug developers to test new drugs on a variety of human cell
types prior to animal and human testing. 37 Thus, only those drugs that
show a potential for safety and efficacy during cell line testing would
move on for further clinical tests required by the FDA. 38 This could
"streamline" the drug development process and reduce research and
development costs for investing corporations. 39
These possible breakthrough developments are still only potential
possibilities. 40 Scientists asserting the possible applications and benefits of
stem cell research note that such developments may be years away,41
because significant technological roadblocks must still be negotiated
before the possibilities become realities. 42 Recognizing the possibilities of
such research and the need for further development, President Bush
announced that federal funding would be provided for stem cell research. 43
In addition, the President created a Council on Bioethics to monitor this
research and to make recommendations for guidelines and regulations. 44
While the President's decision ensures that federally funded research
will be conducted, private companies will continue to fund such research

34. See National Cancer Institute, supra note 24. The National Human Genome Research
Institute is currently using stem cells to study gene expression profiles during cell differentiation.
Id. at 10.
35. See id.
36. Id. See also White House Press Release, supra note 25.
37. National Institutes of Health, supra note 13, at 3.
38. Id.
39. Id. By reducing costs and decreasing the time it takes to receive FDA approval for a

newly developed drug, corporations may be more apt to invest capital in research and development
of drugs.
40. For a more in depth treatment of the possibilities stem cell research offers, see National
Cancer Institute, supra note 24.
41. Id. at 10.
42. See National Institutes of Health, supra note 13, at 4.
43. Remarks by President George W. Bush, supra note 1.
44. See White House Press Release, supra note 25. See also Remarks by President George
W. Bush, supra note 1.
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as well. These investments are made with the ultimate goal of reaping a
profit from the discoveries made. This profit can be made based on patents
granted on the specific procedures used and even on the end results, the
compounds, themselves. Therefore, patent law also plays an important role
in promoting stem cell research. 45

III. UNITED STATES PATENT LAW
A. General History and Purpose

Congressional authority to grant patents to individuals is derived from
the U.S. Constitution. 46 The grant of a patent is a decision of public policy,
whereby the U.S. Government rewards the inventor of a useful invention
that benefits the general public, thus advancing the particular technology
via a limited monopoly on the use of the invention.47 This reward is a
means of inducing creativity and inventions in the sciences.48
The first Patent Act was passed by Congress in 1790.49 Since that time,
several changes have been made, so resulting in the current Patent Act
embodied in Title 35 of the United States Code. 51 This version of the Act
has been modified to comply with international agreements concerning

45. James J. Muchmore, Proprietary Rights and the Human Genome Project: A Legal and
Economic Perspective, 8 DIGEST 45, 48 (2000) (stating that the "possibility ofpatent protection and
property rights in biotechnology provides the potential for great financial return to investors"). See
also Cuenot, supra note 8, at 109 (asserting that patents allow investors to recover their investment
in research and development of an invention, and may also allow them to make a profit on the
patented invention); Alexander K. Haas, The We/lcome Trust's Disclosures ofGene Sequence Data
into the Public Domain & the Potential for Proprietary Rights in the Human Genome, 16
BERKELEY TECH. L.J. 145, 154 (2001) (finding that patent protection provides the biotechnology
industry an incentive to conduct research).
46. In relevant part, Art. I,§ 8, clause 8 of the U.S. Constitution provides that "Congress shall
have power to ... promote the progress of science ... by securing for limited times to ... inventors
the exclusive right to their respective ... discoveries." U.S. CONST. art. I,§ 8, cl. 8.
47. See Cuenot, supra note 8, at 109.
48. See Muchmore, supra note 45, at 48.
49. Patent Act of 1790, ch. 7, §§ 109-112, 1790 Stat. I.
50. See generally DONALDS. CHISUM, CHISUM ON PATENTS apps. 9-1 to 25-1 (2001) (treatise
appendix containing the various Patent Acts and amendments from 1790 through 1988).
SI. 35 U.S.C. §§ 100-157 (2001).
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intellectual property, including the Paris Convention52 and the Agreement
on Trade-Related Aspects of Intellectual Property Rights. 53
B. Requirements for Patentabi/ity
The current version of the Patent Act54 sets forth the requirements that
must be met for an invention to receive a patent. 55 To receive patent
protection, an invention must first involve appropriate subject matter. 56
The invention must also be useful, 57 novel, 58 and non-obvious. 59 In
addition, the invention must be adequately disclosed to enable others to
reproduce the invention and use it successfully. 60 If these requirements are
met, a patent may be issued.
Patentable subject matter comprises "any new and useful process,
machine, manufacture, or composition of matter, or any new and useful
improvement thereof."61 Any possible invention or process, including
compositions of matter such as tissues and organs, that will result from
human stem cell research will pertain to biological organisms. The issue
of whether living, biological organisms, specifically human cells, tissues,
and organs, are patentable subject matter will be addressed in Section IV.
Currently, an invention may meet the requirement of usefulness of 3 5
U.S.C. § 101, often termed the utility requirement, in one of two ways. 62
The inventor need only have a credible assertion ofthe invention's specific
52. International Convention for the Protection of Industrial Property, Mar. 20, 1883, 1883
U.S.T. LEXIS 23.
53. General Agreement on Tariffs & Trade-Multilateral Trade Negotiations (the Uruguay
Round): Agreement on Trade-Related Aspects of Intellectual Property Rights, including trade in
counterfeit goods, Apr. 15, 1994, art. 39, 33 I.L.M. 81, 98 (1994).
54. 35 u.s.c. §§ 100-157 (2001).
55. For purposes of the Act, an invention is any "invention or discovery." Id.§ IO0(a). The
Act also protects a process, which includes a "process, art or method, ... a new use of a known
process, machine, manufacture, composition of matter, or material." Id. § 100(b). See also CHISUM,
supra note 50, at OV-12 (The PTO reviews patent applications and will not issue a patent until
finding that an invention meets the Title 35 requirements); Mark Jagels, Notes and Comments: Dr.
Moreau Has left the Island: Dealing with Human-Animal Patents in the 21st Century, 23 T.
JEFFERSON L. REV. 115, 127 (2000).
56. 35 U.S.C. § 101 (2001). See also CHISUM, supra note 50, § 1.01.
57. 35 u.s.c. § 101 (2001).
58. Id. § 102.
59. Id. § 103.
60. Id. § 112.
61. Id. § 101.
62. See PTO Examination Guidelines on Utility Requirement, SO PAT. TRADEMARK &
COPYRIGHT J.

(BNA) 295 (1995).
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utility or have an apparent belief of its usefulness. 63 This standard is based
on utility guidelines issued by the Patent and Trademark Office (PTO) in
199564 and is easier to meet than the "exacting standard"65 set forth by the
U.S. Supreme Court in Brenner v. Manson. 66 This new standard is
extremely important since the majority of discoveries and inventions that
may result from stem cell research will probably not have a specific
benefit in their initial forms.
The novelty requirement for a patent is embodied in 35 U.S.C. § 102.67
This statutory provision requires an invention to be 'new at the time of
discovery . . . to be patentable. " 68 The invention is not novel if it was
known, used, patented, or described in a publication prior to its invention
by the patent applicant. 69 Public use or sale of the invention prior to the
patent application will also destroy its novelty. 70 However, similar
inventions may already exist without destroying the new invention's
novelty. These prior inventions comprise what is known as the "prior
art."71 Novelty will remain intact so long as no single invention in the prior
art contains the exact identical elements of the new invention. 72 Even if
these requirements are met, a biotechnological invention that involves a
living organism is not novel if it is a naturally occurring phenomenon. 73
Thus, a living organism must be the non-natural result of human
engineering and ingenuity. 74
6

63. See id.
64. See id See also Jagels, supra note 55, at 137.
65. See Jagels, supra note 55, at 137.
66. 383 U.S. 519 ( 1966) (holding that a specific benefit must exist in an available form before
the statutory requirement ofutility is met). See also Mattias Luukkonen, Note, Gene Patents: How
Useful are the New Utility Requirements, 23 T. JEFFERSON L. REV. 337, 351-52 (2001). Brenner
v. Manson still requires an invention's purpose and use to have an immediate value to the public
and must be capable of performing its intended purpose. Id. at 351. However, the PTO revised the
utility guidelines in 2001. Id. at 352. The new requirements are met when a person" ... skilled in
the art [can] appreciate why the invention is useful based on its characteristics." Id.
67. 35 u.s.c. § 102 (2001).
68. See CHISUM, supra note 50, at 3-3.
69. 35 U.S.C. § 102(a) (2001).
70. See id. § 102(b). If the invention was used or sold, the patent application must be filed
within one year from such sale or use in order to retain the invention's novelty. See id. Furthermore,
if the invention has already been described in a pending patent application it cannot be considered
novel./d. § 102(e)(l).
71. See Jagels, supra note 55, at 140.
72. See CHISUM, supra note 50, at 3-6.
73. See Jagels, supra note 55, at 140.
14. Id.
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An invention must also be non-obvious in order to obtain patent
protection. 75 This requirement is not met if, based on the information
found in the prior art at the time of the invention, the invention itself
would be obvious to someone who possessed the ordinary skills in the
relevant art. 76 In addition to this general non-obvious requirement, the
Patent Act sets forth a specific standard for biotechnological inventions. 77
This provision addresses biotechnological processes78 and has been
interpreted as requiring that the prior art lead to the production of the
invention and that there be a reasonable expectation that the invention can
be carried out successfully for the invention to fail the non-obvious
requirement. 79
Even if an invention pertains to appropriate subject matter and is
useful, novel, and non-obvious, it must still meet the enablement and
disclosurerequirementof35 U.S.C. § 112 to obtainapatent. 80 This section
of the Patent Act requires that a written disclosure adequately describing
the invention be provided to the PTO. 81 This writing must be in "full, clear,
concise, and exact terms," and must disclose "the manner and process of
making and using [the invention]."82 This ensures that anyone skilled in
the relevant art will be able to reproduce the invention and employ it for
its specific purpose, thus enabling them to make and use the invention. 83
The writing should also describe the inventor's "best mode" for using the

75.
76.
77.
78.

See 35 U.S.C. § 103 (2001).
See CHISUM, supra note 50, at 5-10, 5-11.
35 U.S.C. § 103(b) (2001).
The Patent Act defines biotechnological processes as:

(A) a process of genetically altering or otherwise inducing a single- or multi-celled
organism to - (i) express an exogenous nucleotide sequence, (ii) inhibit,
eliminate, augment, or alter expression of an endogenous nucleotide sequence, or
(iii) express a specific physiological characteristic not naturally associated with
said organism; (8) cell fusion procedures yielding a cell line that expresses a
specific protein, such as a monoclonal antibody; and (C) a method of using a
product produced by a process defined by subparagraph (A) or (B), or a
combination of subparagraphs (A) and (B).

Id. § 103(b)(3).
79. See Luukkonen, supra note 66, at 349. For an in-depth treatment of the non-obvious
requirement for biotechnological inventions, see CHISUM, supra note 50, at 5-475 to 5-499.
80. 35 u.s.c. § 112 (2001).
81. See id.
82. Id.
83. See id.
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invention. 84 If the written description of the invention provides this
information, then the innovation provided by the invention will be
available to the public and will increase the scope of the prior art. In the
area of biotechnology, the enablement requirement is met if one skilled in
the relevant art can produce and utilize the invention without "undue
experimentation. " 85
IV. PATENT PROTECTION FOR BIOLOGICAL ORGANISMS

A. The Problems ofAppropriate Subject Matter
To receive a patent, an invention must pertain to patentable subject
matter. 86 Prior to 1980, living biological organisms were not considered
patentable subject matter. 87 Inventions involving naturally occurring
biological organisms are considered discoveries of a product of nature. 88
Like natural laws such as the laws of physics, etc., these natural
discoveries were automatically presumed to be unpatentable because they
were not considered inventions. 89 However, this belief was significantly
altered when the U.S. Supreme Court decided Diamond v. Chakrabarty. 90
In this landmark case, the U.S. Supreme Court decided whether a
bacterium, a living biological organism, was patentable subject matter
under 35 U.S.C. § 101.91 Microbiologists genetically modified the
bacterium in question to digest crude oil components. 92 The PTO had
granted a patent for the process used to create these modified bacteria. 93

84. See id.

85. See Luukkonen, supra note 66, at 350 (discussing the success rate and nature of the
invention, the state of the art, and whether the experimentation conducted was routine, as factors
for determining if experimentation required to successfully produce and use a disclosed invention
is considered undue).
86. See supra text accompanying notes 56-61.
87. See Jagels, supra note 55, at 127 (The U.S. Supreme Court decided in 1980 that a living
biological organism could be considered patentable material).
88. Id.
89. See id.
90. 447 U.S. 303 (1980).
91. See id See also Marsha L. Montgomery, Note, Building a Better Mouse-and Patenting
It: Altering the Patent Law To Accommodate Multicellular Organisms, 41 CASE W. RES. L. REV.
231, 238-39 (1990).
92. See Chakrabarty, 447 U.S. at 305.
93. See id.
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However, the bacterium itself was not given patent protection as a
composition of matter. 94 In reversing the PTO's decision, the U.S.
Supreme Court found that the bacterium was not naturally occurring, but
a product of human creation. 95 As a biological organism that had been
genetically altered by humans, the bacterium was not a product of nature
but a "composition of matter" or a "manufacture" per 35 U.S.C. § 101.96
Therefore, the Court held that the organism encompassed patentable
subject matter. 97 In further support of its holding, the Court cited the
Congressional Committee Reports that accompanied the Patent Act,
stating that the intent of Congress was for the Act to apply to "anything
under the sun that is made by man. " 98 However, the Court limited this
holding by requiring that the organism be man-made and not simply
discovered. 99 Thus, after Chakrabarty, certain biological organisms could
be patented.
Seven years after Chakrabarty, a patent application claiming a
genetically engineered multi-cellular organism was filed. too The organism
was not found in nature in this manipulated state, and was therefore
patentable subject matter as a man-made invention. tot As a result of this
patent application, the PTO issued a policy statement regarding the
patentability of multi-cellular biological organisms. to2 The statement
affirmed that non-naturally occurring multi-cellular organisms, including
animals, were patentable subject matter, but emphasized that "[a] claim
directed to or including within its scope a human being [would] not be
considered... patentable subject matter."to3 This ban on patenting human
beings is due to the constitutional prohibition of property rights in

94. See id.
95. See id. at 309.
96. See id. at 307, 310 (quoting 35 U.S.C. § 101 (2001)).
97. See Chakrabarty, 447 U.S. at 307, 310.
98. See id. at 309.
99. See id. See also Jagels, supra note 55, at 128 (stating that Chakrabarty allows organisms
to be patented if they are created via artificial means).
100. See Ex Parle Allen, 2 U.S.P.Q. 2d 1425 (BPAI 1987). {The organism was an oyster).
101. See id. The multi-cellular organism qualified as patentable subject matter under 35 U.S.C.
§ 10 l, however, a patent was denied due to failure to meet the non-obvious requirement. Id. at
1427.
102. Commissioner of Patents and Trademarks, Policy Statement on Patentability of Animals,
1077 OFF. GAZ. PAT. OFF. 24 (1987), reprinted in CHISUM, supra note 50, at app. 24.
103. See id. at app. 24-1.
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humans. 104 However, organisms that include human genes may still be
patentable, as long as they are identified as non-human. 105
Within a year of the PTO' s statement, the first patent was issued for a
genetically modified animal. 106 The animal, a mouse, had been genetically
infused with a human cancer gene and would be used for experimentation
purposes. 107 After the granting of this patent, the floodgates were opened
for other patents involving animals infused with human genes. 108 This
practice went unchallenged by the PTO until 1998 when a patent
application was filed claiming techniques for combining embryonic cells
of humans and animals. 109 In response to this application, the PTO issued
a media advisory to clarify its position on patenting human-related
organisms, stating that such an invention could fail to meet the utility
requirement. 110 However, without referring to the advisory, the patent was
denied for several reasons, including the failure to meet the subject matter
requirement. 111 Despite this particular rejection, it is clear that biological
organisms can meet the statutory subject matter requirement of the Patent
Act.112

B. The Patentability of Human DNA Sequences and Human Genes
The ability to patent genetically manipulated biological organisms
opened the door for researchers to patent specific human DNA 113
sequences, including whole genes. This practice of granting patents to

104. See Montgomery, supra note 91, at 242 (citing the Fourteenth Amendment's ban on
slavery).
10S. See id.
106. See U.S. Patent No. 4,736,866 (issued Apr. 12, 1988). See also Jagels, supra note 5S, at
132.
107. See Jagels, supra note 55, at 132.
108. See id. (stating hundreds of similar patents have been granted since this particular patent).
109. See id.
110. U.S. Patent and Trademark Office Media Advisory, No. 98-6, Facts on Patenting Life
Forms Having a Relationship to Humans, (Apr. 1, 1998). This was based on the seldom used
"morality doctrine," stating that an invention cannot be useful if it is designed for an immoral use.
See Jagels, supra note 55, at 137-38 (discussing the origin and erratic application of this judicial
doctrine).
111. See Jagels, supra note 55, at 133. The patent application also failed to meet the nonobvious and enablement requirements. Id.
112. See CHISUM, supra note 50, at 1-48.
113. DNA molecules contain the genetic material, the hereditary code of an organism. KELLY
ET AL., supra note 12, at 25. Individual genes form the many segments of each DNA molecule.
TORTORA & GRABOWSKI, supra note 11, at 4 7.
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researchers for sequences of human DNA that comprise all or part of a
human gene is known as gene-patenting. 114 DNA, found in the nucleus of
every cell, 115 contains thousands of genes (specific sequences that control
heredity), as well as the requisite information for protein synthesis, and
directs the overall function, proliferation, and differentiation of cells. 116
Since the discovery of the structure of DNA in 1953, researchers have
been able to separate and identify particular gene sequences from the
entire DNA molecule. 117 During this time, several countries and
organizations have attempted to determine the entire human genome-the
sequences and locations of all the genes found in human DNA
molecules. 118 As a result, an international cooperative, the Human Genome
Project, has undertaken this task. 119
In 1991, the first U.S. patent application was filed claiming partial
DNA sequences. 120 In response to this action, private companies and
governmental agencies filed patent applications claiming thousands of
partial DNA sequences. 121 This action led to international criticism. 122
Those opposed to the patenting of human DNA sequences insist that it is
unethical to grant someone property rights in something that is part of the
"universal heritage" of all humans, since these gene sequences are shared
in common by all of humanity. 123 Furthermore, the purpose of the Human
Genome Project is to cooperatively share information in order to expedite
the mapping of the entire human genome. 124 The drive to obtain a profit
through patent rights will diminish the open dissemination of information
during this vital research endeavor. 125
114. See Patricia A. Lacy, Comment, Gene Patenting: Universal Heritage vs. Reward for
Human Effort, 11 OR. L. REV. 783, 784 (1998).
115. See KELLY ET AL., supra note 12, at 25.
1Hi. See Muchmore, supra note 45, at 46-47.
117. See id. at 47.
118. See id.
119. See id.
120. This patent application was filed by the National Institutes of Health. It claimed that the
invention met the statutory requirements, contending that full-length DNA sequences were not
required since they could be gained without undue experimentation. See id. at 49. See G. Kenneth
Smith & Denise M. Kettelberger, Patents and the Human Genome Project, 22 AIPLA Q.J. 27, 46
(1994).
121. See Muchmore, supra note 45, at 49. See also Haas, supra note 45, at ISO (stating that
companies have sought patents for gene sequence data).
122. See Lacy, supra note 114, at 783.
123. See id. at 798.
124. See id.
125. See id. at 792.
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Proponents of patenting human DNA sequences acknowledge the
problems associated with allowing such a policy. 126 However, they insist
that the pursuit and subsequent grant of patents increases the general
knowledge on the subject and leads to the creation of products that are
beneficial to the public. 127 Thus, by allowing patents on DNA sequences,
the PTO will not only encourage, but ensure the continued research and
development of the entire human genome. While both sides have
legitimate arguments, their differing views exemplify the ethical
dichotomy presented by this issue. 128
Facing this ethical issue, the PTO rejected the initial applications
claiming partial DNA sequences, but in 1995, issued a patent to the
National Institute of Health for a genetically developed human cell line. 129
Since those initial filings, the PTO has granted patents on DNA gene
sequences, both partial and complete. 130 By doing so, the PTO has
provided a means of securing proprietary rights in the human genome
through patents. 131 But how can patents be issued on gene sequences since
they are naturally occurring products found in all humans? This problem
has been circumvented by the current human-manipulated organism
subject matter classification. 132 Genes do not naturally exist as individual
compositions of matter. 133 However, once researchers identify particular
gene sequences, these genes can be isolated and considered patentable
subject matter. 134
Although patents have been successfully received for genes and gene
sequences, another problem exists for the issuing of such patents. The
Human Genome Project has already completed a "working draft" of the
human genome's approximately 30,000 genes and should have a final

126. See id. at 797.
127. See Lacy, supra note 114, at 797.
128. See id. at 785. The first question is, "is it ethically permissible to patent segments of the
human genome when these segments represent part of our individual and collective 'natural'
heritage?" while the second question is, "is it ethical to deny patenting parts of the human genome
given the vast economic resources and human effort expended in identifying it?" Id.
129. See id. at 793. See also Muchmore, supra note 45, at 49.
130. See Melissa L. Sturges, Comment, Who Should Hold Property Rights to the Human
Genome? An Application of the Common Heritage of Humankind, 13 AM. U. INT'L L. REV. 219,
234 n.91 (1997) (patents granted to Maryland company for individual genes).
131. See Muchmore, supra note 45, at 49.
132. See supra text accompanying notes 92-99.
133. See Mark Christopher Farrell, Comment, Designer DNA for Humans: Biotech Patent Law
Made Interesting/or the Average Lawyer, 35 GONZ. L. REV. 515, 522 (2000).
134. See id.
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version of the genome map completed within the next two years. 135 In
response to this accomplishment, a medical research charity involved with
the Human Genome Project announced that it would place the raw
sequence of the entire genome into a database readily accessible by the
public. 136 When this sequence data is made available to the public,
researchers will no longer be able to receive patent protection for any
portion of the "raw" genomic sequence, in accordance with sections 102
and 103 of the Patent Act. 137 However, this does not mean that the end
products and other "useful benefits derived from [the] genetic
information" would no longer be patentable. 138 Therefore, while the future
of gene sequence patenting is uncertain, the ultimate innovations from
such research should still retain their patentability.
V. THE PATENTABILITY OF HUMAN CELLS AND ORGANS
Human embryonic stem cell research may lead to technological
processes that could produce, among other things, in vitro human tissues
and organs. 139 This technology would most likely utilize previously
discovered DNA gene sequences as well as those yet to be determined. 140
In addition, these processes and their ultimate end products may also
contain or utilize embryonic stem cells themselves. 141 More importantly,
they would involve a subject matter that is clearly human. Thus, these
possible innovations may not be patentable due to their subject matter. 142

135. See Haas, supra note 45, at 146.
136. See id. at 145. The medical research charity, known as the Wellcome Trust, is the largest
in the world and contributed approximately one-third of the research into the human genome. Id.
at 151.
137. Id. (Once disclosed to the public, these genomic sequences lose their novelty and nonobvious status). See also infra § III.B and accompanying notes for a discussion of the statutory
requirements of the Patent Act.
138. See Haas, supra note 45, at 152 (quoting the Human Genome Organization, HUGO
Statement on Patenting of DNA Sequences, at http://www.gene.ucl.ac.uk/hugo/patent2000.html
(Apr. 2000)). See id. at 158 (products "more removed ... from the raw sequence, would still be
patentable").
139. See infra § 11.B.
140. See National Institutes of Health, supra note 13.
141. See id.
142. Since these theoretical products, which could be considered as compositions of matter
under 35 U.S.C. § 101, must be viewed as human-related, they could be deemed non-patentable
subject matter. See supra text accompanying notes 102-05.
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However, the specific processes used to produce them may still remain
eligible to receive patent protection.
Patents have already been issued for inventions involving specific
procedures for isolating and purifying human embryonic stem cells. Dr.
James Thompson was one of the first researchers to develop a patentable
technique for isolating these cells from the human body, purifying them,
and creating a cell line. 143 One such patent, U.S. Patent number6,200,806,
granted on March 13, 2001, covers claims of specific human embryonic
stem cell lines, including the method used to obtain them. 144 Dr. Thompson
assigned these and other patent rights to the University of Wisconsin
Alumni Research Foundation, which subsequently licensed these rights to
a commercial corporation. 145 This agreement is the subject of a current
lawsuit between the parties regarding the scope of the agreement. 146
However, the validity of the patents have not been challenged. 147
Therefore, it appears that the PTO does not consider a claim of human
stem cell lines to be directed to, or include within its scope, a human
being.
Finding human stem cell lines to be patentable subject matter, the PTO
has issued patents claiming human stem cells as compositions of matter. 148
Such patents have also been held valid in United States courts. For
instance, in Johns Hopkins University v. CellPro, Inc., 149 the U.S. Court of
Appeals for the Federal Circuit found valid a patent claiming a suspension
of human stem cells. 150 The issuing of such patents and the failure of

143. See U.S. Patent No. 6,200,806(issuedMar. 13,2001).Seealso U.S. Patent No. 6,280,718
(issued Aug. 28, 2001) (claiming the method for isolating human embryonic stem cells).
144. See U.S. Patent No. 6,200,806 (issued Mar. 13, 2001), claims 1, 9, 11.
145. University Foundation Sues Over Stem-Cell Patent, INTELL. PROP. LITIG. REP., Sept. 18,
2001, at 8.
146. The University of Wisconsin Alumni Research Foundation (WARF) is suing the Geron
Corporation regarding the extent of the licensing agreement. Id. As of October 30, 200 l, the case
was still in the pleadings stage with Geron filing an answer to the complaint and a motion for
summary judgment on October 3, 2001 and WARF filing a response to the motion on October 30,
2001. See Geron Continues Aggressive Development of Embryonic Stem Cell Technology, Bus.
WIRE, Nov. l, 2001 [hereinafter Geron Continues].
147. See Geron Continues, supra note 146.
148. See, e.g., U.S. Patent No. 4,965,204 (issued Oct. 23, 1990) (monoclonal antibodies and
cells); U.S. Patent No. 6,090,622 (issued Jul. 18, 2000) (human embryonic germ cell line); U.S.
Patent No. 6,117,675 (issued Sept. 12, 2000) (human retinal stem cells).
149. 152 F. 3d 1342, 1368 (Fed. Cir. 1998).
150. See id. at 1356. The type of stem cells involved were not embryonic stem cells, but a
form of adult hematopoietic stem cells, which can form the different types of blood cells found in
the body. Id. at 1346-47.
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subsequent challenges to their validity proves that the patentability of
human cells and biological materials is not within the scope of the PTO
based on its policy statements. 151 However, once stem cell technology
advances to include compositions of matter such as human organs, it is
likely that the PTO will find that any claims to such inventions do violate
the "hwnan scope" policy statement. Thus, it is doubtful that patent
protection will be available for these compositions of matter.
While the extent of patentability of human cells and biological
materials appears unsettled, the patentability of other types of possible end
products of stem cell research, such as new drugs and treatment
techniques, appears to be more firmly established. If these inventions do
not claim human "compositions" as an end product, then they should be
patentable, even if the research methods involved employment of human
stem cells. If the inventions fall under the "human scope" prohibition, the
methods of obtaining these products could still be patentable. To date,
several patents have been issued for the methods utilized in the isolation
and purification of stem cells and in corresponding research. 152 These
methods, along with those developed in the future, must only meet the
patentability requirements set forth in the Patent Act. If they do, they
should qualify for patent protection.

VI. CONCLUSION
The U.S. Government grants patents for useful inventions that benefit
the general public. To receive patent protection, these inventions must be
useful, novel, non-obvious, and adequately disclosed. 153 In addition, they
must involve appropriate subject matter. 154 The PTO has indicated that it
will not view a claim that includes within its scope, or is directed to, a

151. See U.S. Patent and Trademark Office Media Advisory, supra note 110.
152. See, e.g., U.S. Patent No. 5,639,618(issuedJun. 17, 1997)(method for isolating specific
embryonic cells); U.S. Patent No. 5,843,780 (issued Dec. 1, 1998) (claiming a method for isolating
primate embryonic stem cells); U.S. Patent No. 6,030,836 (issued Feb. 29, 2000) (method of
maintaining human stem cells in vitro); U.S. Patent No. 6,090,622 (issued Jul. 18, 2000) (human
embryonic germ cell line); U.S. Patent No. 6,093,531 (issued Jul. 25, 2000) (method of
transforming neural stem cells into hematopoietic cells); U.S. Patent No. 6,117,675 (issued Sept.
12, 2000) (human retinal stem cells and a method for obtaining them); U.S. Patent No. 6,280,718
(issued Aug. 28, 2001) (method for isolating and purifying human embryonic stem cells).
153. See 35 U.S.C. §§ 101-103, 112 (2001).
154. See id. § 101.
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human being, as encompassing patentable subject matter. 155 Therefore,
patent laws may not protect inventions involving human biological
materials.
The PTO's policy of denying patents for human-related subject matter
is based on the constitutional prohibition of slavery. Thus, one cannot have
property rights in humans. Although patents have been allowed for
inventions that are human related, including inventions comprised of
human genetic sequences and isolated and purified human stem cells, this
practice cannot be extended to include the human end products of stem cell
research. If researchers are able to grow human organs, such as kidneys
and livers, in laboratory petri dishes, these inventions should not be
patentable. While these products would definitely be the result of human
genetic manipulation, they should still be considered part of the common
heritage of humankind. In addition, they could not meet the subject matter
requirement used by the PTO at this time. However, the specific processes
and methods for creating such innovations should still remain eligible for
patent protection. This will ensure that the ethical dichotomy is adequately
addressed. Researchers, and their backing investors, will still be rewarded
for their efforts and expenditures in creating technologies that can benefit
the public. At the same time, the ethical and constitutional concerns will
be met.

155. See Commissioner of Patents and Trademarks, supra note 102.

